NEW YORK (GenomeWeb) – Interpace Diagnostics today said that it has regained compliance with a Nasdaq listing requirement calling for at least $2.5 million in stockholder equity.

As a result, the company's shares will remain listed on the Nasdaq Capital Market.

The firm was notified in November that it failed to meet the listing requirement and faced delisting action. On April 10, though, it received a letter from Nasdaq saying it had regained compliance.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.